Bellerophon Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Bellerophon Therapeutics, Inc. carries a market capitalization of 146,791.00, placing it among publicly traded companies globally. Its enterprise value stands at 233,140.01, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 146,791.00 |
| Enterprise Value | 233,140.01 |
Share Statistics
Bellerophon Therapeutics, Inc. currently has 12.23M shares outstanding.
| Shares Outstanding | 12.23M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.82, and the price-to-book ratio stands at -0.02.
| PE Ratio | N/A |
| PS Ratio | 0.82 |
| PB Ratio | -0.02 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | -0.38 |
| P/OCF Ratio | -0.37 |
Enterprise Valuation
| EV / Sales | 0.04 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Bellerophon Therapeutics, Inc. maintains a current ratio of 3.96, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.96 |
| Quick Ratio | 3.49 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -105.23 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -1.28M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Bellerophon Therapeutics, Inc.'s stock has declined approximately -81.27341% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | -81.27341% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.05 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Bellerophon Therapeutics, Inc. generated 5.64M in revenue and converted that into -9.25M in net income, yielding earnings per share of -0.79. EBITDA reached -11.03M, while operating income came in at -11.03M.
| Revenue | 5.64M |
| Gross Profit | N/A |
| Operating Income | -11.03M |
| Pretax Income | -10.53M |
| Net Income | -9.25M |
| EBITDA | -11.03M |
| EBIT | -11.03M |
| Earnings Per Share (EPS) | -0.79 |
Balance Sheet
Total book value stands at -256.19M, with working capital of 3.72M providing operational flexibility.
| Cash & Cash Equivalents | 4.38M |
| Total Debt | N/A |
| Net Debt | -4.38M |
| Equity (Book Value) | -256.19M |
| Book Value Per Share | -22.07 |
| Working Capital | 3.72M |
Cash Flow
Bellerophon Therapeutics, Inc. produced -12.34M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.34M |
| Capital Expenditures | N/A |
| Free Cash Flow | -12.34M |
| FCF Per Share | -1.06 |
Margins
Bellerophon Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -195.66 and net profit margin of -164.06 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -195.66 |
| Pretax Margin | -186.70 |
| Profit Margin | -164.06 |
| EBITDA Margin | -195.55 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -108.51 |
| FCF Yield | -265.47 |
Stock Splits
Bellerophon Therapeutics, Inc.'s most recent stock split took place on February 10, 2020 with a 15:1 split ratio.
| Last Split Date | 2/10/2020 |
| Split Ratio | 15:1 |
Scores
Bellerophon Therapeutics, Inc. posts an Altman Z-Score of -75.15, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -75.15 |